Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of “Buy” by Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has earned an average recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $11.25.

Several analysts have recently commented on the company. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Friday, January 10th. Finally, Roth Mkm began coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $7.00 price target for the company.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC lifted its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Performance

NASDAQ RVPH opened at $1.77 on Friday. The stock’s 50 day simple moving average is $1.64 and its 200 day simple moving average is $1.31. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.83.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.